Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Rigel Pharmaceuticals, Inc. (RIGL) -- Ignore unavailable to you. Want to Upgrade?

To: tuck who wrote (203)	6/11/2004 4:12:03 PM
From: tuck	Read Replies (2) \| Respond to of 566

And just when we were wondering what was happening with the ubiquitin ligase program . . . >>South San Francisco, CA - June 09, 2004 Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that it has been granted United States Patent Nos. 6,737,244 and 6,740,495, relating to its program in ubiquitin ligases. These fundamental patents cover methods for identifying and/or measuring E3 ubiquitin ligase activity and screening for agents that modulate their activity, including small molecule or biological modulators. Rigel believes that it is a leader in characterizing and exploiting the ubiquitin ligase system for the discovery of potentially new therapeutics. It has one of the industry's broadest efforts, working on numerous ligase targets. Rigel was one of the first companies to discover potent and highly selective small molecule inhibitors of ubiquitin ligase targets. Some of these inhibitors have shown good activity in animal models of disease and are in pre-clinical development. "Rigel's breadth and experience in the field of ubiquitin ligases, now buttressed by these key patents, give Rigel a significant competitive advantage in this nascent field," said Donald G. Payan, M.D., Rigel's Executive Vice President and Chief Scientific Officer, "Ubiquitin ligases play an important role as targets for potential treatments for oncology, inflammatory and viral diseases as well as other important areas." Rigel has entered into ubiquitin ligase collaborations with key industry partners. In 2002, Rigel began working with Daiichi Pharmaceuticals Co. Ltd. on a specific ubiquitin ligase target that controls cancer cell proliferation. Additionally, in late 2003, Johnson & Johnson accepted a ubiquitin ligase target in oncology as part of its collaboration with Rigel. About Ubiquitin Ligases Ubiquitin ligases play a key role in protein localization and protein turnover within the cell. Modulation of these targets presents a novel approach to treating diseases where the normal cell processes are out of balance, such as in cancer where the cell cycling is abnormal. Ubiquitin ligase cancer targets play a role in the regulation of stability, localization, and activity of key proteins such as oncoproteins. Ubiquitin ligase targets are numerous and modular. This provides the potential for intervening in a highly specific fashion in a disease, potentially improving efficacy and minimizing side-effects.<< snip Cheers, Tuck